Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration.
Multiple sclerosis is a currently incurable inflammatory demyelinating syndrome. Recent reports suggest that bone marrow derived mesenchymal stem cells may have therapeutic potential in experimental models of demyelinating disease, but various alternative mechanisms, ranging from systemic immune effects to local cell replacement, have been proposed. Here we used intraperitoneal delivery of human mesenchymal stem cells to help test (a) whether human cells can indeed suppress disease, and (b) whether CNS infiltration is required for any beneficial effect. We found pronounced amelioration of clinical disease but profoundly little CNS infiltration. Our findings therefore help confirm the therapeutic potential of mesenchymal stem cells, show that this does indeed extend to human cells, and are consistent with a peripheral or systemic immune effect of human MSCs in this model.
Gordon
David
D
MS Stem Cell Group, Burden Neurological Institute, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1LE, UK.
Pavlovska
Gordana
G
Glover
Colin P
CP
Uney
James B
JB
Wraith
David
D
Scolding
Neil J
NJ
D000818:Animals; D034961:Antigens, Nuclear / Q000378:metabolism; D017690:Cell Transplantation / Q000502:physiology*; D002490:Central Nervous System / Q000276:immunology*; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000276:immunology* / Q000628:therapy*; D006023:Glycoproteins / Q000008:administration & dosage; D049452:Green Fluorescent Proteins / Q000235:genetics; D006801:Humans; D007274:Injections, Intraperitoneal / Q000379:methods; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments / Q000008:administration & dosage; D012720:Severity of Illness Index; D014162:Transfection / Q000379:methods; D014183:Transplantation, Heterologous / Q000379:methods
D034961:Antigens, Nuclear; D006023:Glycoproteins; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments; C445081:myelin oligodendrocyte glycoprotein (35-55); D049452:Green Fluorescent Proteins